CS
IMUC

Credit Suisse’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Credit Suisse’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-931
Closed -$42K – 4910
2014
Q2 		$42K Buy
931
+235
+34% +$11.3K ﹤0.01% 4601
2014
Q1 		$34K Sell
696
-2,775
-80% -$136K ﹤0.01% 4601
2013
Q4 		$128K Buy
+3,471
New +$329K ﹤0.01% 4434
2013
Q3 		– Sell
-5,429
Closed -$422K – 4565
2013
Q2 		$422K Buy
+5,429
New +$520K ﹤0.01% 3416

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return